ENDO 2025 12 - 15 July 2025

Efficacy and safety of somapacitan in non-GHD adolescents with short stature: 26-week results from the REAL9 phase 3 study

Authors :

Aristides Maniatis¹; Michael Højby²; Muhammad Yazid Jalaludin³; Alexander A. L. Jorge⁴; Jun Mori⁵; Kamil Soltysik²; Renata Stawerska^6,7; Agnéès Linglart⁸.

Affiliations

View Details Hide Details

Download PDF

Keywords

Rare Endocrine Disorder

Congress poster

Somatropin

Search Science Hub

Are you a healthcare professional?

Efficacy and safety of somapacitan in non-GHD adolescents with short stature: 26-week results from the REAL9 phase 3 study